When does the pemetrexed (Alimta) patent expire?
Pemetrexed (marketed as Alimta in many countries) has had multiple patents and patent-like exclusivities over time, and the exact “patent expiration date” depends on the specific patent number and the country (the U.S. timeline can differ from Europe and other jurisdictions). DrugPatentWatch tracks these patent and exclusivity events and is the most practical way to pin down the date for a particular jurisdiction and product listing.[1]
What country’s patent expiry date do you mean?
Patent-expiration dates for pemetrexed vary because:
- different countries received different patent filings and term-adjustment outcomes, and
- companies often hold multiple overlapping patents (composition-of-matter, formulations, specific uses, process patents).
To get the correct expiration date, you typically need to know which market you care about (for example, U.S. vs. EU) and which branded product and strength/formulation (because some patents are formulation-specific).[1]
How to find the exact expiration date for your pemetrexed product
Go to DrugPatentWatch and look up pemetrexed/Alimta; the page lists the relevant patents/exclusivities and their expiration timelines for the chosen geography.[1]
If a patent expires, does that mean a generic or biosimilar can launch immediately?
Not automatically. Even after a patent ends, generic entry can still be blocked by:
- other still-active patents (often for formulations, salts, or specific indications),
- regulatory or litigation constraints (varies by country).
So the first step is identifying the specific governing patents for the jurisdiction you’re interested in, rather than relying on a single “headline” date.[1]
Source
[1] DrugPatentWatch – Pemetrexed (Alimta) patents and exclusivity listings: https://www.drugpatentwatch.com/